Cargando…

A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience

BACKGROUND/AIMS: The widespread use of cytotoxic chemotherapy and immunosuppressants has resulted in reactivation of hepatitis B virus (HBV) recently becoming an issue. Although rituximab (an anti-CD20 monoclonal antibody) has revolutionized the treatment of lymphoma, recent reports have suggested t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Myung Jin, Lee, Heon Ju
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622856/ https://www.ncbi.nlm.nih.gov/pubmed/23593610 http://dx.doi.org/10.3350/cmh.2013.19.1.51

Ejemplares similares

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

PB2312: REACTIVATION OF HEPATITIS B VIRUS FOLLOWING RITUXIMAB IN B LYMPHOID HEMOPATHIES
por: Wafa, Miled, et al.
Publicado: (2023)

Late Hepatitis B reactivation after treatment with rituximab
por: Pereira, Sara Lacerda, et al.
Publicado: (2022)

Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study
por: Tsai, Yu-Fen, et al.
Publicado: (2019)

Real-world experience of rituximab biosimilar GP2013 in rheumatoid arthritis patients naïve to or switched from reference rituximab
por: Łosińska, Katarzyna, et al.
Publicado: (2023)

Hepatitis Virus Reactivation in Patients with Psoriasis Treated with Secukinumab in a Real-World Setting of Hepatitis B or Hepatitis C Infection
por: Megna, Matteo, et al.
Publicado: (2022)

Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
por: Lee, Yong-Pyo, et al.
Publicado: (2021)

A case report of hepatitis B virus reactivation 19 months after cessation of chemotherapy with rituximab
por: Guo, Xiangjuan, et al.
Publicado: (2022)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Carotid Artery Stenting: A Single Center “Real World” Experience
por: Krasniqi, Nazmi, et al.
Publicado: (2012)

Real world data on follicular lymphoma patients treated by rituximab-containing immunochemotherapy and rituximab maintenance
por: Kim, Hee Kyung, et al.
Publicado: (2020)

Antiviral Efficacy of Entecavir versus Entecavir plus Adefovir for Hepatitis B Virus rtA181V/T Mutants Alone
por: Oh, Myung Jin, et al.
Publicado: (2016)

Rituximab in Rasmussen’s encephalitis: A single center experience and review of the literature
por: Jagtap, Sujit A., et al.
Publicado: (2022)

The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience
por: Nissen, Johanna C, et al.
Publicado: (2014)

PB2105: REAL WORLD EXPERIENCE WITH POLATUZUMAB IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB FOR R/R DLBCL IN 3 ACADEMIC CENTERS IN MADRID, SPAIN.
por: Corrochano, M., et al.
Publicado: (2022)

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019)

Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy
por: Hayashi, Manabu, et al.
Publicado: (2018)

External validation of the SEDAN score: The real world practice of a single center
por: Muengtaweepongsa, Sombat, et al.
Publicado: (2015)

Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
por: Shin, Hyun Phil, et al.
Publicado: (2017)

Real world evidence: Patients with refractory pemphigus treated with Rituximab
por: Perifani, Vagiani, et al.
Publicado: (2021)

Rituximab, lenalidomide and BTK inhibitor as frontline treatment for elderly or unfit patients with diffuse large B-cell lymphoma: a real-world analysis of single center
por: Zhu, Yanan, et al.
Publicado: (2022)

Correction: Carotid Artery Stenting: A Single Center “Real World” Experience
por: Krasniqi, Nazmi, et al.
Publicado: (2012)

Real-world use of PCSK9 inhibitors: A single-center experience
por: Sarsam, Sinan, et al.
Publicado: (2018)

Vaccinations in patients with multiple sclerosis: a real-world, single-center experience
por: Sbragia, Elvira, et al.
Publicado: (2022)

Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival
por: Chen, Kai-Lin, et al.
Publicado: (2015)

Rituximab in Refractory Myasthenia Gravis: Experience in a Single Healthcare Center in Mexico
por: López-Hernández, Juan Carlos, et al.
Publicado: (2021)

Efficacy and Safety of Direct-Acting Antiviral Therapy in Patients With Chronic Hepatitis C Virus Infection: A Real-World Single-Center Experience in Tianjin, China
por: Xia, Huan, et al.
Publicado: (2020)

Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma
por: Muraishi, Junichi, et al.
Publicado: (2017)

Using health-system-wide data to understand hepatitis B virus prophylaxis and reactivation outcomes in patients receiving rituximab
por: Schmajuk, Gabriela, et al.
Publicado: (2017)

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Real-world single-center experience with direct-acting antivirals for improvement of the liver fibrosis after chronic hepatitis C treatment
por: Lee, Sun Hee, et al.
Publicado: (2020)

Hepatitis B reactivation in patients with pemphigus vulgaris after immunosuppressive therapy including rituximab
por: Yoo, Dae San, et al.
Publicado: (2020)

Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience
por: Katsuno, Takayuki, et al.
Publicado: (2017)

Impact of cluster of differentiation 20 expression and rituximab therapy in classical Hodgkin lymphoma: Real world experience
por: Abuelgasim, Khadega A., et al.
Publicado: (2021)

Biosimilar Rituximab (Redditux) Added to CHOP Chemotherapy for De Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single-Center Experience
por: Özbalak, Murat, et al.
Publicado: (2022)

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience
por: Agarwal, Amit, et al.
Publicado: (2021)

Real‐world experience: Introduction of T cell replete haploidentical transplantations in a single center
por: van Gorkom, Gwendolyn, et al.
Publicado: (2021)

Real-world outcomes and toxicity of adjuvant chemotherapy in NSCLC: a single-center experience
por: Cronin, Christopher, et al.
Publicado: (2023)

Steroid-Resistant Graves’ Orbitopathy Treated with Tocilizumab in Real-World Clinical Practice: A 9-Year Single-Center Experience
por: Pérez-Moreiras, José V., et al.
Publicado: (2021)

Low-dose Rituximab therapy in resistant idiopathic membranous nephropathy: single-center experience
por: Bagchi, Soumita, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_at3ubr6oir1lbgsq6mpa7t9jai